Nanomedicine applications towards the cure of HIV

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 1, 2013, Pages 28-38

  Lisziewicz, Julianna ^a,b   Toke, Eniko R ^a  

^a Genetic Immunity Kft   (Hungary)

^b Genetic Immunity Inc   (United States)

Author keywords

Drug development; HIV eradication; HIV vaccine; Memory T cells

Indexed keywords

ANTIRETROVIRAL DRUGS; ANTIRETROVIRALS; CLINICAL TRIAL; DRUG DEVELOPMENT; HIV ERADICATION; INFECTED CELLS; LONG LASTING; MEMORY T CELLS; MICROBICIDES; T CELLS; T-CELL RESPONSE; VIRAL LOAD; VIRUS ELIMINATION;

CELLS; CURING; CYTOLOGY; MEDICAL NANOTECHNOLOGY; PATIENT TREATMENT; VIRUSES;

DISEASES;

EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; NEVIRAPINE; PLACEBO; RITONAVIR; SAQUINAVIR; WART VIRUS VACCINE;

ANTIVIRAL RESISTANCE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION PREVENTION; LOW DRUG DOSE; NANOMEDICINE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; VIRUS LOAD;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHEMISTRY, PHARMACEUTICAL; HIV; HIV INFECTIONS; HUMANS; NANOMEDICINE;

EID: 84871416782     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.05.012     Document Type: Review

References (80)

1. Barré-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1993, 220:868-871.
2. Blattner W., Gallo R.C., Temin H.M. HIV causes AIDS. Science 1998, 241:515-516.
3. Gallo R.C. Historical essay. The early years of HIV/AIDS. Science 2002, 298:1728-1730.
4. Gallo R.C., Montagnier L. The discovery of HIV as the cause of AIDS. N Engl J Med 2003, 394:2283-2285.
5. UNAIDS Report on the Global AIDS Epidemic 2010. http://www.unaids.org/globalreport/Global_report.htm.
6. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., et al. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus infection. New Engl J Med 1998, 338:853-860.
7. Holtgrave D.R. Causes of the decline in AIDS deaths, United States, 1995-2002: Prevention, treatment or both?. Int J STD AIDS 2005, 16:777-781.
8. Losina E., Schackman B.R., Sadownik S.N., Gebo K.A., Walensky R.P., et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009, 49:1570-1578.
9. Baker J.V., Peng G., Rapkin J., Abrams D.I., Silverberg M.J., et al. CD4+ count and risk of NON-AIDS diseases following initial treatment for HIV infection. AIDS 2008, 22:841-848.
10. Mavigner M., Delobel P., Cazabat M., Dubois M., L'faqihi-Olive F.E., et al. HIV-1 residual viremia correlates with persisitent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009, 4:e7658.
11. Casazza J.P., Betts M.R. Picker LJ and Koup RA Decay kinetics of Human Immunodeficiency Virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 2001, 75:6508-6516.
12. Allers K., Hütter G., Hofmann J., Loddenkemper C., Rieger K., et al. Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood 2011, 117:2791-2799.
13. Lisziewicz J., Rosenberg E., Lieberman J., Jessen H., Lopalco L., et al. Control of HIV despite the discontinuation of antiretroviral therapy. New Engl J Med 1999, 340:1683-1684.
14. Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
15. Hatano H., Hayes T.L., Dahl V., Sinclair E., Lee T.H., et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011, 203:894-897.
16. Shan L., Dend K., Shroff N.S., Durand C.M., Alireza S., et al. Stimulation of HIV-1-Specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:1-11.
17. Vyas T.K., Shah L., Amiji M.M. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 2006, 3:613-628.
18. Amiji M.M., Vyas T.K., Shah L.K. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov Med 2006, 6:157-162.
19. Nowacek A., Gendelman H.E. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine 2009, 4:557-574.
20. Kovochich M., Marsden M.D., Zack J.A. Activation of latent HIV using drug-loaded nanoparticles. PLoS One 2011, 6:e18270.
21. Choi S.U., Bui T., Ho R.J. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to enatrap a solute. J Pharm Sci 2008, 97:931-943.
22. Kinman L., Brodie S.J., Tsai C.C., Bui T., Larsen K., et al. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study i HIV-2287-infected macaques. J Acquir Immune Defic Syndr 2003, 34:387-397.
23. Ma X., Wang D., Wu Y., Ho R.J.Y., Jia L., et al. AIDS treatment and novel anti-HIV compounds improved by nanotechnology. AAPS J 2010, 12:272-278.
24. Chiappetta D.A., Hocht C., Taira C., Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailabilty. Nanomedicine 2010, 5:11-23.
25. Baert L., van't Klooster G., Dries W., François M., Wouters A., et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009, 72:502-508.
26. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
27. NIH Discontinues Tenofovir Vaginal Gel in 'VOICE' HIV Prevention Study. http://www.nih.gov/news/health/nov2011/niaid-25.htm.
28. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61:158-171.
29. Das Neves J., Amiji M., Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?. John Wiley and Sons Inc 2011, 3:389-399.
30. Grabovac V., Bernkop-Schnurch A. Development and in vitro evaluation of surface modified poly (lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine. Drug Dev Ind Pharm 2007, 33:767-774.
31. Wang Y.Y., Lai S.K., So C., Schneider C., Cone R., Hanes J. Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One 2011, 6:e21547.
32. Kish-Catalone T., Pal R., Parrish J., Rose N., Hocker L. Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model. AIDS Res Hum Retroviruses 2007, 23:33-42.
33. Caron M., Besson G., Etenna S.L., Mintsa-Ndong A., Mourtas S. Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV. Virology 2010, 405:225-233.
34. Pornpattananangkul D., Olson S., Aryal S., Sartor M., Huang C.-M., et al. Stimuli-responsive liposome fusion mediated by gold nanoparticles. ACS Nano 2010, 4:1935-1942.
35. Lara H.H., Ixtepan-Turrent L., Garza-Trevino E.N., Rodriguez-Padilla C. PVP-coated silver nanoparticles block the transmission of cel.l-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnol 2010, 8:1-11.
36. Martinez-Avila O., Bedoya L.M., Marradi M., Clavel C., Alcami J., et al. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 transinfection of human T cells. Chem Biochem 2009, 10:1806-1809.
37. Mamo T., Moseman E.A., Kolishetti N., Salvador-Morales C., Shi J., et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine 2010, 5:269-285.
38. Rupp R., Rosenthal S.L., Stanberry L.R. VivaGel (SPL 7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomed 2007, 2:561-566.
39. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., et al. Induction of potent immune responses by cationic microparticles with adsorbed Human Immunodeficiency Virus DNA vaccines. J Virol 2001, 75:9037-9043.
40. Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults. http://www.clinicaltrials.gov/ct2/show/NCT00073216?term=PLG+HIV&rank=1.
41. Spearman P., Lally M.A., Elizaga M., Montefiori D., Tomaras G.D., et al. A Trimeric, V2-DELETED HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011, 203:1165-1173.
42. Xiang S.D., Scholzen A., Minigo A., David C., Apostolopoulos V., et al. Pathogen recognition and development of particulate vaccines: Does size matter?. Methods 2006, 40:1-9.
43. Lisziewicz J., Szebeni J. The Janus face of immune stimulation by nanomedicines examples for the good and the bad. Eur J Nanomed 2010, http://dx.doi.org/10.3884/0003.1.5.
44. Christensen N.D., Hopfl R., Diangelo S.L., Cladel N.M., Patrick S.D., et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994, 75:2271-2276.
45. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial. JAMA 2007, 298:743-753.
46. Martin S.J., Vyakarnam A., Cheingsong-Popov R., Callow D., Jones K.L., et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS 1993, 7:1315-1323.
47. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008, 60:915-928.
48. Lamalle-Bernard D., Munier S., Compagnon C., Charles M.H., Kalyanaraman V.S., Delair T., Verrier B., Ataman-Onal Y. Coadsorption of HIV-1 P24 and GP120 Proteins to surfactant-free anionic PLA Nanoparticles preserves antigenicity and immunogenicity. J Control Release 2006, 115:57-67.
49. Fairman J., Moore J., Lemieux M., Van Rompay K., Geng Y., Warner J., Abel K. Enhanced in VIVO Immunogenicity of SIV Vaccine Candidates with cationic liposome-DNA Complexes In a Rhesus macaque Pilot Study. Hum Vaccin 2009, 5:141-150.
50. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006, 112:26-34.
51. Diebold S.S., Kursa M., Wagner E., Cotton M., Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cell. J Biol Chem 1999, 274:19087-19094.
52. Natz E., Lisziewicz J. Rational design of formulated DNA vaccines: the DermaVir approach, in gene vaccines 2011, 109-125. Springer Wien, New York. J. Thalhamer, R. Weiss, S. Scheiblhofer (Eds.).
53. Tomalia D.A. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 2009, 11:1251-1310.
54. Somogyi E., Xu J., Gudics A., Tóth J., Kovács A., et al. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine 2011, 29:744-753.
55. Toke E.R., Lorincz O., Somogyi E., Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm 2010, 392:261-267.
56. Lorincz O., Toke E.R., Somogyi E., Horkay F., Chandran P.L. Structure and biological activity of pathogen-like synthetic nanomedicines. Nanomedicine: NMB 2011, in press.
57. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M., Ott R.G., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467:591-595.
58. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006, 27:573-579.
59. Schaffer D.V., Fidelman N.A., Dan N., Lauffenburger D.A. Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotech Bioeng 2000, 67:598-606.
60. Han X., Fang Q., Yao F., Wang X., Wang J. The heterogeneous nature of polyethylenimine-DNA complex formation affects transient gene expression. Cytotechnology 2009, 60:63-75.
61. Suh J., Wirtz D., Hanes J. Efficient active transport of gene nanocarriers to the nucleus. Proc Natl Acad Sci 2003, 100:3878-3882.
62. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
63. Nicolas J.F., Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7:1201-1214.
64. Bauer J., Bahmer F.A., Worl J., Neuhuber W., Schuler G., et al. A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope. J Invest Dermatol 2001, 116:313-318.
65. Lisziewicz J., Gabrilovich D.I., Varga G., Xu J., Greenberg P.D., et al. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol 2001, 75:7621-7628.
66. Lisziewicz J., Trocio J., Whitman L., Varga G., Xu J., et al. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol 2005, 124:160-169.
67. Lisziewicz J., Trocio J., Xu J., Whitman L., Ryder A., et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005, 19:35-43.
68. Lisziewicz J., Bakare N., Calarota S.A., Bánhegyi D., Szlávik J. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One 2012, 7:e35416.
69. Calarota S.A., Foli A., Maserati R., Baldanti F., Paolucci S., et al. HIV-1-Specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 2008, 180:5907-5915.
70. Rodriguez B, Asmuth D, Matining R, Spritzler J, Li X, et al. Repeated-dose transdermal administration of DermaVir, a candidate plasmid DNA-based therapeutic HIV vaccine, is safe and well-tolerated: a 61-week analysis of ACTG Study 5176, paper presented at XVIIIth International AIDS Conference, 2010, Vienna, Austria, Abstract # A-240-0111-10145.
71. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010, 363:411-422.
72. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005, 5:783-792.
73. Shen L., Siliciano R.F. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immun 2008, 122:22-28.
74. Dinosoa J.B., Kima S.Y., Wiegandc A.M., Palmerc S.E., Ganged S.J., et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009, 106:9403-9408.
75. Gandhi R.T., Zheng L., Bosch R.Z., Chan E.S., Margolis D.M., et al. The effect of Raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2011, 7:1-11.
76. McMahon D., Jones J., Wiegand A., Gange S.J., Kearney M., et al. Short-course Raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010, 50:912-919.
77. DermaVir Search Results. Accessed 12 January 2012. http://www.clinicaltrials.gov/ct2/results?term=dermavir.
78. Fuller D.H., Loudon P., Schmaljohn P. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006, 40:86-97.
79. Aline F., Brand D., Pierre J., Roingeard P., Séverine M., et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 2009, 27:5284-5291.
80. Kalams S.A., Parker S., Jin X., Elizaga M., Metch B. Safety and immunogenicity of AN HIV-1 GAG DNA vaccine with or without il-12 and/or il-15 plasmid cytokine adjuvant in healthy, hiv-1 uninfected adults. PLoS One 2012, 7:E29231.